Every parliamentary written question tabled by Andrew Cooper this session, with the full answer and department. See how every department answers, or back to the MP page.
Showing 41–47 of 47 · Department of Health and Social Care
What recent estimate he has made of the number of people in (a) Mid Cheshire constituency, (b) Cheshire and (c) England who have unmet care needs; and what steps his Department is taking to help en
Local authorities are responsible for assessing individuals’ care and support needs and, where eligible, for meeting those needs. Where individuals do not meet the eligibility threshold, they can get support from their local authorities in making their ow...
What recent estimate his Department has made of the number of (a) adults and (b) children in Mid Cheshire constituency who (i) are not registered with an NHS dentist and (ii) have been unable to ac
Patients in England are not registered with a National Health Service dental practice, although many NHS dental practices do tend to see patients regularly. There is no geographical restriction on which practice a patient may attend, allowing patients the...
What steps he is taking to improve patient access to primary care in (a) Mid Cheshire constituency, (b) Cheshire and (c) England.
We are committed to fixing the crisis in primary care to secure the long-term sustainability of the National Health Service and increase access to local services across the country.We are also committed to moving towards a Neighbourhood Health Service, wi...
What the average waiting time was for mental health treatment in (a) Mid Cheshire constituency, (b) Cheshire and (c) England in each of the last three years.
A table showing the average waiting time for mental health treatment for the Mid Cheshire constituency, Cheshire, and England for those aged over 18 years old, and another table for those aged under 18 years old, for each of the last three years, is attac...
What steps he plans to take to help improve access to ADHD medication.
The Department has been working with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of intensive work, some issues have been resolved. All strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available. We are working to resolve medicine supply issues, where they remain, for some strengths of methylphenidate. These are anticipated to be resolved by October 2024.We are asking suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term.The Department has worked with specialist clinicians to develop management advice for National Health Service clinicians to consider prescribing available alternative brands of methylphenidate prolonged release tablets. We would expect ADHD service providers and specialists to follow our guidance to offer rapid response to primary care teams seeking urgent advice or opinion for the management of patients, including those known to be at a higher risk of adverse impact because of these shortages.To aid ADHD service providers and prescribers further, we have widely disseminated our communications and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients, which is available at the following link:https://www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd/
What steps his Department is taking to tackle shortages in ADHD medications.
The Department has been working hard with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of this intensive work, some issues have been resolved. Many strengths of lisdexamfetamine and all strengths of atomoxetine capsules and guanfacine prolonged-release tablets are now available. We are working to resolve medicine supply issues, where they remain, for some strengths of lisdexamfetamine and methylphenidate. These are anticipated to resolve by August and October 2024, respectively.We are asking suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term.The Department has worked with specialist clinicians to develop management advice for National Health Service clinicians, to consider prescribing available alternative brands of methylphenidate prolonged release tablets. We would expect ADHD service providers and specialists to follow our guidance to offer rapid response to primary care teams seeking urgent advice for the management of patients, including those known to be at a higher risk of adverse impact because of these shortages.To aid ADHD service providers and prescribers further, we have widely disseminated our communications, and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients. Further information is available at the following link:https://www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd/
What progress his Department has made on producing statutory guidance under the Down Syndrome Act 2022.
The Department is currently considering next steps on producing the Down syndrome statutory guidance, as required under the Down Syndrome Act 2022, and further information will be provided in due course.Officials have engaged with stakeholders to progress the development of draft guidance. This has included the establishment of an advisory group to inform the development process, and carrying out a national call for evidence and review of the evidence to gain a better understanding of the specific needs of people with Down syndrome and how these can be met by relevant authorities. The call for evidence received over 1,500 responses, including responses from people with Down syndrome, their families and carers, professionals, organisations, and stakeholder groups representing people with genetic conditions.